Company
Scientific roots, experienced leadership and institutional support behind the development of BT-101
Company at a glance
BOOST Pharma is a clinical-stage biotech company developing BT-101 for children with severe Osteogenesis Imperfecta (OI). The company builds on scientific work originating at Karolinska Institutet in Sweden and operates from Copenhagen, Denmark.
BOOST’s current focus is on the clinical, regulatory and organizational activities needed to enable initiation of the planned pivotal Phase III study.
Headquarters
Copenhagen, Denmark
Scientific origins
Karolinska Institutet, Sweden
Lead program
BT-101 for severe pediatric Osteogenesis Imperfecta
Development stage
Phase III-ready
Selected company milestones
2025
Sound Bioventures joined the investor syndicate.
2025
Longer-term follow-up from BOOSTB4 was presented.
2024
Positive FDA pre-IND feedback supported the planned path toward pivotal Phase III.
2024
Industrifonden and KDventures joined the investor base.
2023
Final dosing was completed in the Phase I/II BOOSTB4 study.
2021/22
BT-101 received Orphan Drug Designation in the EU and US, and FDA Rare Pediatric Disease Designation.
2020
First patient was dosed in the Phase I/II BOOSTB4 study.
Team
Hans T. Schambye, MD, PhD
CEO
Experienced biotech executive and company builder with a track record of leading development-stage life science companies.
Lilian Walther Jallow, PhD
Co-founder & CDO
Cell therapy development specialist with deep experience in CMC, product development, and advancing the BT-101 program.
Anthony Hall, MB BS Bsc AKC FFPM FRSM
CMO
Rare disease physician-executive with extensive orphan drug development experience and a strong focus on patient-centered clinical development.
Louise Himmelstrup
CRO
Regulatory leader with experience in global development strategy and advancing rare disease programs toward approval.
Fredrik Lehmann, PhD
CMC Advisor
Biotech entrepreneur and CMC expert with experience in manufacturing, process development and scale-up readiness.
Board
Elaine V. Jones, PhD
Chair
Biopharmaceutical executive and investor with more than 20 years of life science investing, board, research and business development experience.
Ingelise Saunders, M.Sc. Pharm.
Board Member
Senior biotech and pharmaceutical leader with more than 35 years of C-level executive and board experience.
John Öhd, MD, PhD
Board Member
Physician-scientist and biotech executive with senior R&D leadership experience at AstraZeneca, Shire and Medivir.
Jonathan Ilicki, MD, MBA
Board Member
Physician, researcher and investor representative from Industrifonden, bringing medical, investment and company-building experience.
Magnus Westgren, MD, PhD
Board Member
Senior Professor at Karolinska Institutet who established fetal therapies in Sweden and performed the world’s first prenatal MSC transplantation.
Ester Sklarsky, M.Sc.
Board Member
Life science investor and Principal at Sound Bioventures with experience in biotech investing, scientific and strategic due diligence and board-level company development.
Johan Kördel, PhD
Board Observer
Life science investor and company builder with senior experience across Pharmacia, Biovitrum and Sound Bioventures.
Scientific Advisors
Prof. Jörg Oliver Semler, PhD, MD
Scientific Advisor
Internationally recognized OI expert and pediatric specialist with extensive experience in skeletal dysplasias.
Prof. Willem E. Fibbe, PhD, MD
Scientific Advisor
Internationally recognized expert in stem cell therapies and clinical development using advanced therapy medicinal products.
Prof. Cecilia Götherström, PhD
Co-founder & Scientific Advisor
Karolinska stem cell scientist whose research has been central to the scientific foundation behind BT-101.
Cathleen L. Raggio, PhD, MD
Scientific Advisor
Orthopedic surgeon and OI specialist, Chair of the OI Foundation Medical Advisory Council and Co-Director of the Center for Skeletal Dysplasias.
Backed & supported by
BOOST Pharma is backed by Nordic life science investors and has received support from leading innovation institutions.
The BOOSTB4 clinical study was separately supported through academic and public research funding.
Backed by
Supported by
- The Danish Growth Fund (Vækstfonden)
- Innovation Fund Denmark
BOOSTB4 study
- EU Horizon 2020
- Swedish Research Council
- Karolinska Institutet (study sponsor)
Explore Next
Science
Biological and scientific rationale
BT-101
Program concept and treatment approach
Clinical
Development progress and next steps
News
Latest news and events